Premium
Multisite study of the relationships between antemortem [ 11 C]PIB‐PET Centiloid values and postmortem measures of Alzheimer's disease neuropathology
Author(s) -
La Joie Renaud,
Ayakta Nagehan,
Seeley William W.,
Borys Ewa,
Boxer Adam L.,
DeCarli Charles,
Doré Vincent,
Grinberg Lea T.,
Huang Eric,
Hwang JiHye,
Ikonomovic Milos D.,
Jack Clifford,
Jagust William J.,
Jin LeeWay,
Klunk William E.,
Kofler Julia,
LesmanSegev Orit H.,
Lockhart Samuel N.,
Lowe Val J.,
Masters Colin L.,
Mathis Chester A.,
McLean Catriona L.,
Miller Bruce L.,
Mungas Daniel,
O'Neil James P.,
Olichney John M.,
Parisi Joseph E.,
Petersen Ronald C.,
Rosen Howard J.,
Rowe Christopher C.,
Spina Salvatore,
Vemuri Prashanthi,
Villemagne Victor L.,
Murray Melissa E.,
Rabinovici Gil D.
Publication year - 2019
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2018.09.001
Subject(s) - neuropathology , positron emission tomography , medicine , autopsy , pathology , nuclear medicine , senile plaques , alzheimer's disease , disease
We sought to establish the relationships between standard postmortem measures of AD neuropathology and antemortem [ 11 C]PIB–positron emission tomography ([ 11 C]PIB‐PET) analyzed with the Centiloid (CL) method, a standardized scale for Aβ‐PET quantification. Methods Four centers contributed 179 participants encompassing a broad range of clinical diagnoses, PET data, and autopsy findings. Results CL values increased with each CERAD neuritic plaque score increment (median −3 CL for no plaques and 92 CL for frequent plaques) and nonlinearly with Thal Aβ phases (increases were detected starting at phase 2) with overlap between scores/phases. PET‐pathology associations were comparable across sites and unchanged when restricting the analyses to the 56 patients who died within 2 years of PET. A threshold of 12.2 CL detected CERAD moderate‐to‐frequent neuritic plaques (area under the curve = 0.910, sensitivity = 89.2%, specificity = 86.4%), whereas 24.4 CL identified intermediate‐to‐high AD neuropathological changes (area under the curve = 0.894, sensitivity = 84.1%, specificity = 87.9%). Discussion Our study demonstrated the robustness of a multisite Centiloid [ 11 C]PIB‐PET study and established a range of pathology‐based CL thresholds.